Research & Development
Thyroid Cancer: Page 2
Second guessing thyroid cancer test | Artificial intelligence on show | Companies gear up for AACC
Dear LabPulse Member,
July 22, 2019
Popular rule-out test for thyroid cancer draws scrutiny
The researchers believe that their analysis of data from the Afirma GEC test (Veracyte) indicates the test may not live up to the results found in the pivotal trial used for the product's introduction (New England Journal of Medicine, August 23, 2012, Vol. 367:8, pp. 705-715). As a result, clinicians might want to recommend more aggressive follow-up of nodules classified as benign by the test.
July 18, 2019
Sonic touts ThyroSeq results at AACE 2019
ThyroSeq can help avoid diagnostic surgeries for suspected thyroid cancer by distinguishing between benign and cancerous nodules, according to the company. ThyroSeq testing has been expanded into cytology smears, which may be the only specimens available when a dedicated sample is not collected for molecular testing. With ThyroSeq, patients with indeterminate cytology won't have to make another visit to a physician's office to have another sample taken; instead, the available smears can be sent for testing.
April 28, 2019
Page 2 of 2